The methodology is developed within the EHRN’s Regional Program “Harm Reduction Works—Fund It!", funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund). The Program aims at strengthening advocacy by civil society, including people who use drugs, for sufficient, strategic, and sustainable investments in harm reduction as HIV prevention in the region of Eastern Europe and Central Asia (EECA). To achieve goal and objectives set HPP, in collaboration with EHRN, developed financial tools for undertaking harm reduction funding advocacy. The methodology includes following tools: Harm Reduction Expenditure Tracking Tool captures the actual expenditures for all cost categories of Needle and Syringe Programs (NSP) and Opioid Substitution Therapy (OST) for the last two fiscal years. The tool also enables monitoring of resources for the key harm reduction programs. Harm Reduction Unit Costing Tool estimates the unit cost for harm reduction, i.e., the cost of an NSP and OST client per year. The tool is, therefore, beneficial for decision-makers who budget for harm reduction programs. Harm Reduction Funding Gap Tool estimates the resource gap for harm reduction.
EHRN has attended the 58th session of CND, the central policymaking body on narcotic drugs within the UN, with a key message of the importance of regional approach to drug policies.
The International Journal of Drug Policyprovides a forum for the dissemination of current research, reviews, debate, and critical analysis on drug use and drug policy in a global context. It seeks to publish material on the social, political, legal, and health contexts of psychoactive substance use, both licit and illicit. The journal is particularly concerned to explore the effects of drug policy and practice on drug-using behaviour and its health and social consequences. It is the policy of the journal to represent a wide range of material on drug-related matters from around the world.
This is the report of the Consultation on Police and HIV, which took place in Amsterdam, Netherlands, on October 4, 2014. The Consultation was held over one day, Saturday 4 October 2014, in Amsterdam, in conjunction with the 2nd International Conference on Law Enforcement and Public Health. The Consultation was able to capitalize on the presence there of many supportive police, civil society and HIV programmes. This Consultation came about as a result of the recognition of a need for co-ordination and collaboration between all agencies working with police in the HIV response, and better planning and sharing of resources and experience. It was convened by the Law Enforcement and HIV Network (LEAHN), and co-organized by the Centre for Law Enforcement and Public Health (CLEPH), the International Development Law Organization (IDLO) and Birkbeck School of Law at the University of London.
European Harm Reduction Network (EuroHRN) will organize a training on harm reduction for local drug policies. Interested activists are invited to apply.
The European Harm Reduction Network (EuroHRN) is organizing a series of trainings on harm reduction for local drug policies. Three trainings will cover 3 sub-regions: Northern Europe, Southern Europe and Central and Eastern Europe. The objective is to train 24 national advisers for 24 different EU countries in order to support, at national level, drug services in their local partnership-based development. The outline of the trainings provides more information on the rationale, aims, trainings methods, expectations from participants.
According to the latest update on the global state of harm reduction published in 2010, OST is available in 70 countries and territories around the world. The global coverage is estimated at the level of between 6 and 12 OST clients per 100 PWID and reaching as high as 61 OST recipients per 100 PWID in Western Europe and 52 OST recipients per 100 PWID in Iran. However, in most countries of Eurasia, coverage is limited due to long-term pilots and the lack of systematic scale-up. The purpose of this paper is to provide an up-to-date overview of the state of OST service provision in Eurasia, with a particular focus on access and quality issues.
This training toolkit has been developed by the International Drug Policy Consortium (IDPC) and the Eurasian Harm Reduction Network (EHRN) to build the capacity of civil society organisations for engaging with, and influencing, drug policy making processes. This toolkit can be used by anybody wishing to deliver trainings and workshops on drug policy advocacy to their civil society partners and members. It covers the areas of drug policy, civil society advocacy and harm reduction, and is intended as a comprehensive menu of activities and content from which a facilitator can pick and choose the ones which best suit the context, audience and timeframe.
The WHO Regional Office for Europe has launched an action plan to contain the spread of drug- resistant TB in the region by the end of 2015. This action plan was prepared in consultation with representatives of the 53 countries of the WHO European Region, experts, patients and communities affected by the disease. The plan takes into account new diagnostic techniques, patient-centered models of care and services tailored to special populations. It includes six strategic directions, such as collaboration on more effective drugs, vaccines and testing, and seven areas of intervention, such as improving access to testing and treatment. If fully implemented, the plan is expected, by 2015, to diagnose 225,000 MDR-TB patients within three days of presenting to a healthcare service with TB symptoms, to successfully treat 127,000 MDR-TB patients, and to prevent the emergence of 250,000 new MDR-TB and 13,000 new XDR-TB cases.
This report prepared by the ACTION Partnership—a network of civil society advocacy organizations working to mobilize new resources against tuberculosis (TB)—aims to give TB a ‘human face’ by looking behind the statistics to focus on the every-day challenges faced by patients and their caregivers. Their personal stories should inform any policy change and must be taken into account by local governments in order to achieve a comprehensive TB response that respects the rights of the patients.